Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Behrend (Munich, Germany), M. Spella (Rio, Greece), M. Pepe (Munich, Germany), G. Giotopoulou (Munich, Germany), M. Lianou (Rio, Greece), I. Giopanou (Rio, Greece), A. Lamort (Munich, Germany), G. Stathopoulos (Munich, Germany). Mapping of Kras mutations during chemical carcinogenesis. 660

Member's Comments

No comment yet.

Related content which might interest you: PP134 – Mapping of Kras mutations during chemical carcinogenesis Source: ERS Lung Science Conference 2021 Year: 2021 Mapping of KRAS mutations during chemical carcinogenesis Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020 LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Mutation of TP53 and KRAS, and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Alteration patterns of tobacco carcinogens in lung adenocarcinoma reveal novel KRAS-addicted candidate oncogenes Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Target other gene point mutations: HER2 and rare EGFR mutations Source: ERS Research Seminar Year: 2015 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 Detection of k-ras codon 12 mutations in human lung tumour tissue by REMS-PCR Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Inhibition of hypoxia-induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast Source: Eur Respir J 2016; 47: 997-1000 Year: 2016 Genetic polymorphisms of k-ras gene in smoking related diseases Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011